IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

iBio, Inc.

600 Madison Avenue
Suite 1601
New York, NY 10022
United States

Full Time Employees43

Key Executives

Mr. Robert B. KayExec. Chairman & CEO310.73kN/A77
Mr. Robert L. ErwinPres2.3MN/A64
Mr. James P. Mullaney CPACFO & Principal Accounting Officer86.67kN/A46
Mr. Terence E. Ryan Ph.D.Chief Scientific Officer200kN/A62
Dr. Renato LoboChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.

Corporate Governance

iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.